Ranking by Regions
United States
Canada
Mexico
Brazil
Chile
Germany
United Kingdom
France
Spain
Netherlands
Sweden
Italy
Switzerland
Poland
Finland
China
Japan
South Korea
Hong Kong
Singapore
Indonesia
India
Malaysia
Taiwan
Thailand
Australia
New Zealand
Israel
Saudi Arabia
Turkey
Russia
South AfricaRanking by categories
As of January 22, 2025, AbbVie (ABBV) has a market cap of $299.69 billion USD. According to our data, AbbVie is ranked No.33 in global market value.
| Year | Market Cap | %Change |
|---|---|---|
| Jan 22, 2025 | $299.69 B |
-3.66%
|
| Dec 31, 2024 | $311.09 B |
18.86%
|
| Dec 29, 2023 | $261.73 B |
-0.23%
|
| Dec 30, 2022 | $262.34 B |
24.01%
|
| Dec 31, 2021 | $211.55 B |
32.43%
|
| Dec 31, 2020 | $159.75 B |
27.72%
|
| Dec 31, 2019 | $125.08 B |
1.47%
|
| Dec 31, 2018 | $123.27 B |
-0.96%
|
| Dec 29, 2017 | $124.46 B |
60.07%
|
| Dec 30, 2016 | $77.75 B |
9.79%
|
| Dec 31, 2015 | $70.82 B |
-6.50%
|
| Dec 31, 2014 | $75.74 B |
27.92%
|
| Dec 31, 2013 | $59.21 B |
100%
|
| Name | Market Cap | Market cap difference | Regions |
|---|---|---|---|
 Pfizer
PFE
|
$149.69 B |
-1.275 B
|
USA
|
 Johnson & Johnson
JNJ
|
$344.10 B |
0.003 M
|
USA
|
 Merck
MRK
|
$242.90 B |
-0.007 M
|
USA
|
 Bristol-Myers Squibb
BMY
|
$114.88 B |
-0.811 B
|
USA
|
 Amgen
AMGN
|
$147.39 B |
-0.333 B
|
USA
|
 Gilead Sciences
GILD
|
$115.25 B |
-0.604 B
|
USA
|
 Eli Lilly
LLY
|
$670.90 B |
3.292 B
|
USA
|
 Novartis
NVS
|
$197.89 B |
-1.499 B
|
Switzerland
|
 GlaxoSmithKline
GSK
|
$68.73 B |
-0.194 B
|
UK
|
 Sanofi
SNY
|
$129.28 B |
-0.313 B
|
France
|
 AstraZeneca
AZN
|
$211.74 B |
0.000 M
|
UK
|
 Biogen
BIIB
|
$20.75 B |
0.203 B
|
USA
|
 Regeneron Pharmaceuticals
REGN
|
$76.77 B |
2.434 B
|
USA
|
| Market Cap | = | ABBV Stock Price | * | ABBV Shares Outstanding |
| = | $169.59 | * | 1.77 B | |
| = | $299.69 B |